Life sciences venture investment looks like it’s having a good run so far this year, according to a new report from CB Insights and PwC.
Of course, much of that boost is coming from hefty investments in Grail and Vir Biotechnology ($900 million and $150 million, respectively). Absent that, the numbers fail to dazzle quite so much.
If you gaze back to 2015, when life sciences companies were exiting left and right, you see Q1 VC investment at $2.8 billion in 193 deals. Take Q1 2016, and the investment hits $3.1 billion in 169 deals. And Q1 2017 is at $3.7 billion with 190 deals — so it certainly has the appearance of trending up.